Deals, pipeline updates and geopolitical issues drove the conversation at the 2025 JP Morgan Healthcare conference.

Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Novartis AG (NYSE:NVS), a global healthcare powerhouse with a market capitalization of $208.27 billion, has recently transformed into a pure-play pharmaceutical company, sharpening its focus on its ...

With its Q4 2024 financials on Friday, Novartis (NYSE:NVS) (OTCPK:NVSEF) indicated a delayed timeline for initial data from a ...

Used in consumer products since the 1950s, perfluoroalkyl and polyfluoroalkyl substances (PFAS) are synthetic chemicals with strong fluorine-carbon bonds, earning them the nickname ‘forever chemicals’ ...

Horizon 2 eventually premiered out-of-competition at the Venice Film Festival on Sept. 7, and it was announced today that the delayed sequel will hold its U.S. premiere during the Santa Barbara ...

During Trump’s 2017-2021 tenure, Indian pharma equities faced challenges, including increased FDA regulatory actions that raised compliance costs and U.S. distribution channel consolidation that ...

First Horizon shares have surged 63% in the past year, driven by favorable regulatory prospects and strong financial performance. The bank's Q4 earnings beat estimates, adjusting for a strategic ...

Belite Bio currently has no debt on its balance sheet, which is quite unusual for a cash-burning pharma, which typically has high debt relative to its equity. This means that the company has been ...